Cargando…

Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone is a hydroxy-1,4-naphthoquinone analogue of ubiqu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiorillo, Marco, Lamb, Rebecca, Tanowitz, Herbert B., Mutti, Luciano, Krstic-Demonacos, Marija, Cappello, Anna Rita, Martinez-Outschoorn, Ubaldo E., Sotgia, Federica, Lisanti, Michael P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085139/ https://www.ncbi.nlm.nih.gov/pubmed/27136895 http://dx.doi.org/10.18632/oncotarget.9122

Ejemplares similares

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
por: Fiorillo, Marco, et al.
Publicado: (2016)

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
por: Lamb, Rebecca, et al.
Publicado: (2015)

Two-compartment tumor metabolism: Autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells
por: Salem, Ahmed F., et al.
Publicado: (2012)

Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)
por: Fiorillo, Marco, et al.
Publicado: (2019)

Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?
por: Sotgia, Federica, et al.
Publicado: (2011)

Genetic Induction of the Warburg Effect Inhibits Tumor Growth
por: Sotgia, Federica, et al.
Publicado: (2012)

Cancer Metabolism: New Validated Targets for Drug Discovery
por: Sotgia, Federica, et al.
Publicado: (2013)

The reverse warburg effect in osteosarcoma
por: Sotgia, Federica, et al.
Publicado: (2014)

Insight into glucocorticoid receptor signalling through interactome model analysis
por: Bakker, Emyr, et al.
Publicado: (2017)

Targeting hypoxic response for cancer therapy
por: Paolicchi, Elisa, et al.
Publicado: (2016)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

Cancer stem cells (CSCs): metabolic strategies for their identification and eradication
por: De Francesco, Ernestina M., et al.
Publicado: (2018)

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2018)

Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2017)

Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
por: Fiorillo, Marco, et al.
Publicado: (2017)

Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
por: Pentimalli, Francesca, et al.
Publicado: (2023)

Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition
por: Lamb, Rebecca, et al.
Publicado: (2014)

Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state
por: Alhammad, Rashed, et al.
Publicado: (2020)

Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy
por: Lamb, Rebecca, et al.
Publicado: (2015)

Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERRα Pathway
por: Brindisi, Matteo, et al.
Publicado: (2020)

Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

Hallmarks of the cancer cell of origin: Comparisons with “energetic” cancer stem cells (e-CSCs)
por: Sotgia, Federica, et al.
Publicado: (2019)

“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
por: Fiorillo, Marco, et al.
Publicado: (2019)

Cancer stem cell metabolism
por: Peiris-Pagès, Maria, et al.
Publicado: (2016)

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells
por: De Luca, Arianna, et al.
Publicado: (2015)

Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment
por: Sotgia, Federica, et al.
Publicado: (2011)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
por: Bonuccelli, Gloria, et al.
Publicado: (2016)

Impaired OXPHOS Complex III in Breast Cancer
por: Owens, Kjerstin M., et al.
Publicado: (2011)

p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification
por: Tian, Kun, et al.
Publicado: (2018)

High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy
por: Fiorillo, Marco, et al.
Publicado: (2021)

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells
por: Lamb, Rebecca, et al.
Publicado: (2015)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2019)

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy
por: Fiorillo, Marco, et al.
Publicado: (2018)

MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity In Vivo
por: Sargiacomo, Camillo, et al.
Publicado: (2021)

Roadmap to personalized medicine
por: Qattan, Malak, et al.
Publicado: (2012)

Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production
por: Fiorillo, Marco, et al.
Publicado: (2020)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
por: Ozsvari, Bela, et al.
Publicado: (2017)

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase
por: Fiorillo, Marco, et al.
Publicado: (2021)

Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction
por: Lamb, Rebecca, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bkvh6c8qu614m8304mjl95s4sn